HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.

Abstract
We developed 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl} propionic acid (T-5224) as a novel inhibitor of the c-Fos/activator protein-1 for rheumatoid arthritis therapy. We predicted the metabolism of T-5224 in humans by using human liver microsomes (HLM), human intestinal microsomes (HIM), recombinant human cytochrome P450 (P450), and UDP-glucuronosyltransferases (UGTs). T-5224 was converted to its acyl O-glucuronide (G2) by UGT1A1 and UGT1A3 and to its hydroxyl O-glucuronide (G3) by several UGTs, but it was not metabolized by the P450s. A comparison of the intrinsic clearances (CL(int)) between HLM and HIM suggested that the glucuronidation of T-5224 occurs predominantly in the liver. UGT1A1 showed a higher k(cat)/K(m) value than UGT1A3 for G2 formation, but a lower k(cat)/K(m) value than UGT1A3 for G3 formation. A high correlation was observed between G2 formation activity and UGT1A1-specific activity (β-estradiol 3-glucuronidation) in seven individual HLM. A high correlation was also observed between G2 formation activity and UGT1A1 content in the HLM. These results strongly suggest that UGT1A1 is responsible for G2 formation in human liver. In contrast, no such correlation was observed with G3 formation, suggesting that multiple UGT isoforms, including UGT1A1 and UGT1A3, are involved in G3 formation. G2 is also observed in rat and monkey liver microsomes as a major metabolite of T-5224, suggesting that G2 is not a human-specific metabolite. In this study, we obtained useful information on the metabolism of T-5224 for its clinical use.
AuthorsShinsuke Uchihashi, Hiroyuki Fukumoto, Makoto Onoda, Hiroyoshi Hayakawa, Shin-ichi Ikushiro, Toshiyuki Sakaki
JournalDrug metabolism and disposition: the biological fate of chemicals (Drug Metab Dispos) Vol. 39 Issue 5 Pg. 803-13 (May 2011) ISSN: 1521-009X [Electronic] United States
PMID21346002 (Publication Type: Journal Article)
Chemical References
  • 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid
  • Antirheumatic Agents
  • Benzophenones
  • Glucuronides
  • Isoenzymes
  • Isoxazoles
  • Recombinant Proteins
  • Transcription Factor AP-1
  • Cytochrome P-450 Enzyme System
  • UDP-glucuronosyltransferase, UGT1A3
  • Glucuronosyltransferase
Topics
  • Animals
  • Antirheumatic Agents (metabolism)
  • Arthritis, Rheumatoid (drug therapy)
  • Benzophenones (analysis, chemistry, metabolism, pharmacology)
  • Cytochrome P-450 Enzyme System (metabolism)
  • Glucuronides (metabolism)
  • Glucuronosyltransferase (metabolism)
  • Haplorhini
  • Humans
  • Hydrolysis
  • Intestinal Mucosa (metabolism)
  • Intestines (drug effects, enzymology)
  • Isoenzymes (metabolism)
  • Isoxazoles (analysis, chemistry, metabolism, pharmacology)
  • Liver (drug effects, enzymology, metabolism)
  • Microsomes (drug effects, enzymology, metabolism)
  • Microsomes, Liver (metabolism)
  • Rats
  • Recombinant Proteins (metabolism)
  • Transcription Factor AP-1 (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: